Search the Global News on Pharmaceutical Services
A comprehensive source of news from the pharmaceutical industry. With the latest from pharmaceutical organisations around the globe, we deliver an extensive summary of news, press releases and information directly from companies and other authoritative industry news sources.
Search and filter the results by company or location to find the news that matters to you.
Save
This Search |
View as Grid
| Order by Recently Added
| Order
by Company Name
- Total Results: 573
- Total Pages: 12
MIMETAS and Roche enter into a collaboration
MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to characterize novel compounds in inflammatory bowel disease (IBD) and hepatitis B virus infections (HBV). Under the terms of the agreement, MIMETAS is eligible to receive an upfront payment and milestone payments from Roche.
View original story »
Basic Profile
TreeFrog Therapeutics secures $75M in Series B financing
TreeFrog Therapeutics, a privately held French-based biotech startup focused on developing safe and affordable stem cell-derived cell therapies for millions of patients, today announced the successful closing of a $75 million (€64M) Series B financing round, bringing the total funding to date to $83 million (€70M).
View original story »
Basic Profile
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda
WATERTOWN, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it has entered into a strategic licensing agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to develop targeted, next-generation gene therapies for two indications within the field of lysosomal storage disorders. The collaboration leverages Selecta’s ImmTOR platform to enable…
Read more on this story »
Basic Profile
Ethypharm to acquire Altan Pharma
Thanks to the strong presence of Altan Pharma in Spain, Ethypharm will reach full commercial coverage of the top 5 European markets upon closing, which is expected in the second half of 2021. Ethypharm will also benefit from an enlarged portfolio of high quality hospital injectable products and a rich pipeline of R&D projects, which fit perfectly with its existing Critical Care franchise.
View original story »
Basic Profile
Labcorp Completes Acquisition Of Myriad Autoimmune’s Vectra Testing Business
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 13, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of select operating assets and intellectual property (IP) from Myriad Genetics’ autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay.Earlier this year, Labcorp entered into a definitive agreement to acquire Myriad’s Vectra
Read more on this story »
Basic Profile
Integer to Construct New Innovation and Manufacturing Facility in Galway, Ireland
PLANO, Texas, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, today announced it will further expand its presence in Galway, Ireland, with the construction of a new Medical Device Innovation and Manufacturing facility in the Parkmore East area of Galway. This new facility is required to meet increased demand for regional research, development and manufacturing capabilities as well as capacity for catheters and delivery systems.…
Read more on this story »
Basic Profile
Launch of ten23 health
Basel, September 1, 2021. ten23 health®, a new, globally operating contract development and manufacturing organization (CDMO), announced its launch today. The company will support biotech start-ups and established pharmaceutical customers in developing safe injectable biopharmaceutical drugs for patients.
View original story »
Basic Profile
Seqirus is currently developing a number of sa-mRNA-based influenza vaccine candidates
“While the COVID-19 pandemic has brought mRNA vaccines to prominence, Seqirus has been researching sa-mRNA as a viable influenza vaccine technology for a number of years and is now forging ahead into clinical trials to ensure we build the best possible technology platform for both seasonal influenza and pandemic response, more broadly,” said Stephen Marlow, General Manager at Seqirus. “As part of Seqirus’ investment in this next-generation sa-mRNA technology, I’m proud to announce the appointment of Roberta Duncan in the newly-created role of Vice President, mRNA Program…
Read more on this story »
Basic Profile
Acino and Pharmax collaborate to align with UAE’s strategy to become a regional pharmaceutical manufacturing hub
21 June, 2021; Dubai, United Arab Emirates – Acino, a leader and trusted partner in high-quality pharmaceutical products and services, today announced it has entered into a strategic partnership with the UAE based Pharmax Pharmaceuticals, that will form a major step in aligning with the UAE’s aspirations towards becoming a regional pharmaceutical manufacturing hub for innovative and similar medicines.
View original story »
Basic Profile
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland
BERLIN and BRISBANE, Australia, July 28, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences (“atai” or the “Company”) (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and UniQuest, Australia’s leading university technology transfer company commercializing the research of The University of Queensland (UQ), today announced the launch of InnarisBio Inc. (InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders.
Read more on this story »
Basic Profile
Bionical Emas to establish European storage, distribution, and labelling facility in Co. Westmeath, creating 35 jobs
Kilbeggan, Co. Westmeath. 9th August 2021. Bionical Emas, a global Contract Research Organisation (CRO) providing a range of services to the pharmaceutical and Biotech sector, is to establish a storage, distribution, and secondary labelling facility in Ireland. Bionical Emas will be initially creating some 35 new local jobs.
View original story »
Basic Profile
MVC COVID-19 Vaccine Obtains Taiwan EUA Approval
TAIPEI, TAIWAN --July 19th, 2021. Medigen Vaccine Biologics Corp (MVC) obtains Taiwan EUA approval due to MVC’s COVID-19 vaccine has fulfilled following EUA standards set by Taiwan’s regulatory agencies:1.For the GMT of MVC-COV1901, the lower bound of 95% confidence interval (CI) is 3.4 times the GMT of AstraZeneca. (Set criteria: 0.67 times the GMT of AstraZeneca.) 2.For the sero-response rate of MVC-COV1901, the lower bound of 95% CI achieved 95.5%, which far exceeded the set threshold of 50%.
Read more on this story »
Basic Profile
SP Doubles Global Manufacturing Capacity for Fill-Finish and Freeze Dryers to Meet Increasing Demand
SP Scientific Products (SP) announces that to stay ahead of the ever-increasing global demand for its state-of-the-art fill-finish and lyophilization (freeze dryer) equipment, it has more than doubled its worldwide manufacturing capacity. Central to this expansion is the opening of a new large-scale manufacturing facility in Barcelona, Spain, for SP i-Dositecno sterile fill-finish systems. SP is also increasing its manufacturing headcount and streamlining many of its manufacturing processes. These strategic advancements are already ensuring reduced order-to-delivery lead…
Read more on this story »
Basic Profile
Swiss Government turns to swissfillon for COVID-19 test kit production
Visp, Switzerland, July 7, 2021: Swissfillon AG, a leading Swiss Drug Product Contract Manufacturing Organisation specializing in the sterile filling of pharmaceuticals, has supplied 0.8 million aseptically filled transport media in syringes for the Swiss Army Pharmacy’s COVID-19 PCR test kit. The project began back in March 2020, when the Swiss Army Pharmacy approached Swissfillon. The mandate to provide testing capabilities for Switzerland’s 8.6 million population was urgent.
View original story »
Basic Profile
Batavia to develop innovative clinical process for RocketVax’s second generation COVID-19 vaccine
Leiden, 6 July 2021 – Today, Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus.
View original story »
Basic Profile
Fertin Pharma and associated companies acquired by Philip Morris International
EQT announced today that it has agreed to sell Fertin Pharma, a specialist contract development and manufacturing organization (CDMO) in innovative oral and intra-oral delivery technologies, to Philip Morris International (PMI) (NYSE: PM). With headquarters in Vejle, Denmark, Fertin Pharma is a leading specialist CDMO in innovative oral and intra-oral delivery technologies to support healthier living. The Company develops and manufactures innovative delivery systems, such as chewing gums, tablets, and powders, used for pharmaceutical and nutraceutical applications.…
Read more on this story »
Basic Profile
BioMed X and Merck KGaA, Darmstadt, Germany launch new research program in oncology
Heidelberg, Germany, July 5, 2021 – BioMed X, a leading independent research institute, announced today the start of its eighth joint research program with Merck KGaA, Darmstadt, Germany. The new program will explore the role of extrachromosomal DNA in cancer and it will complement the research of two ongoing oncology programs at BioMed X in the fields of DNA damage response and RNA…
Read more on this story »
Basic Profile
Viralgen increases its manufacturing capacity with the opening of a new facility for commercial production
Viralgen has been serving the rapidly expanding gene therapy market with its robust AAV manufacturing platform since 2018, supporting customers in preclinical through phase 2. Viralgen’s new facility, located in the same technology park as Viralgen’s existing manufacturing footprint, expands capacity more than 5-fold and enables full support of customer projects from early pre-clinical through to commercial scale. Equipment validation and facility certification activities will continue throughout 2021 with the first commercial-grade 2,000L batches released by mid-2022. This expansion has been…
Read more on this story »
Basic Profile
Ortec, Inc breaks ground in Newcastle West, Ireland
Newcastle West, May 14, 2021, Ortec, Inc., a leading supplier of contract formulation and manufacturing services to the life science industry, has announced that construction has begun on its European Headquarters, Manufacturing and Operations Centre in Newcastle West, Co. Limerick. The privately-owned company communicated its intention to establish its European HQ at Newcastle West in 2016 and is now pleased to progress the development.
View original story »
Basic Profile
PerkinElmer Agrees to Acquire Viral Vector Gene Delivery Leader SIRION Biotech
WALTHAM, Mass.–(BUSINESS WIRE)–Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector-based technologies that drive improved delivery performancefor cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based in Germany, the U.S. and France. The company has…
Read more on this story »
Basic Profile
GENEZEN BREAKS GROUND ON CGMP LENTIVIRAL VECTOR PRODUCTION FACILITY
Genezen Laboratories, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has broken ground on a new multiphase master plan for a 75,000+ square foot cGMP-compliant Lentiviral vector production facility.
View original story »
Basic Profile
Entegris Expands Life Sciences Production Capacity and Capabilities
Billerica, MA – Entegris, Inc. (NASDAQ: ENTG), a world-class supplier of advanced materials and process solutions for the semiconductor and other high-technology industries, today announced the expansion of its Life Sciences manufacturing facilities located in Billerica, MA; Bloomington, MN; and Logan, UT.
View original story »
Basic Profile
Cellenkos® Selects Cryoport to Support On-Demand, Flexible COVID-19 Therapy Shipments to Patients in Need
NASHVILLE, Tenn., June 22, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or "the Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that Cellenkos®, Inc., a privately held, clinical-stage biotechnology company, has selected Cryoport to provide a staged, on-demand, logistics solution for COVID-19 therapy shipments for patients in need.
View original story »
Basic Profile
WHO voices concerns over Sputnik V Covid vaccine plant
WHO reports issues with quality control data and test results as Slovakia announces it is offloading 160k doses
View original story »
Basic Profile
AbCellera to Build Antibody Manufacturing Facility in Canada
VANCOUVER, British Columbia, -- AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new antibody therapies to clinical trials, supporting Canada’s efforts to respond quickly and effectively to future pandemics and providing AbCellera’s partners with a full solution for accelerating their programs…
Read more on this story »
Basic Profile
Long-suffering Dendreon finds new avatar as contract manufacturer for cell therapy partners
Filing for bankruptcy in 2014 might have seemed the end for Dendreon. But seven years later—and three rounds of being bought and sold—the company has resurfaced. This week, Dendreon revealed plans to establish a CMO division offering end-to-end manufacturing of complex…
Read more on this story »
Basic Profile
Exelead Helps Manufacture Pfizer-BioNTech Covid-19 Vaccine
INDIANAPOLIS — Exelead, Inc., a contract development and manufacturing company providing complex medicines to customers and their patients, delivered its first vaccine precursor batch manufactured at its facility, as part of an agreement with Pfizer for the Pfizer-BioNTech COVID-19 Vaccine. In its recently expanded, state-of-the-art facilities, Exelead is supporting production of the vaccine by dedicating a portion of its manufacturing capacity to this effort. “We are extremely proud to be part of the manufacture…
Read more on this story »
Basic Profile
Yposkesi launches construction of its second bioproduction site.
Corbeil-Essonnes (near Paris), France, June 14, 2021 – Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, today announces the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy M
View original story »
Basic Profile
Ori and Vineti Partner for Manufacturing and Supply Chain Solutions in CGT
LONDON and SAN FRANCISCO, May 26, 2021 (GLOBE NEWSWIRE) — Ori Biotech, an innovator in cell and gene therapy manufacturing, and Vineti, a provider of leading digital enterprise platforms for cell and gene therapy supply chains, today announces that the companies will partner to produce a fully pre-integrated solution to modernize, fast-track, and streamline the manufacture and delivery of cell and gene therapies (CGTs).
View original story »
Basic Profile
VIVEbiotech Increases Viral Vector manufacturing capacity
VIVEbiotech’s production capacity will increase by 400%, with an increase in average batch size per year from 20 in 2020 to 80 in 2022.
View original story »
Basic Profile
CPL Completes Successful Virtual Health Canada Audit
June 2, 2021, Mississauga, Ontario, Canada— Contract Pharmaceuticals Limited Canada (CPL), a Health Canada and US FDA inspected manufacturer of liquid and semi-solid prescription and regulated OTC products, has successfully completed a virtual cGMP audit of its manufacturing facility by Health Canada. Since the onset of the global pandemic, CPL has focused on keeping our employees safe while also continuing to deliver product for our customers. One innovation was to create a 360° virtual tour that “walks” our customers and regulators…
Read more on this story »
Basic Profile
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
WILMINGTON, Mass.--(BUSINESS WIRE)--May 17, 2021-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions. The purchase price is expected to be $292.5 million in cash, subject to customary closing adjustments. In addition to the initial purchase price, the transaction includes contingent additional payments of up…
Read more on this story »
Basic Profile
NJ Bio Moves Headquarters to Princeton, New Jersey
PRINCETON, N.J.--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey. The 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by
Read more on this story »
Basic Profile
Gene therapy 'development engine' scores $120M to beef up contract manufacturing
COLUMBUS, OH, April 29, 2021 – Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the closing of a $120 million Series B financing. The financing was led by RA Capital Management with participation from Perceptive Advisors and related affiliates, Surveyor Capital (a Citadel company), Octagon Capital, and Marshall Wace. Existing investors Perceptive Xontogeny Venture Fund and Drive Capital also participated. In connection with the financing, Matthew Hammond, Ph.D., of RA Capital, and Fred Callori of the Perceptive Xontogeny Venture Fund…
Read more on this story »
Basic Profile
RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt
Moscow/Cairo/Berlin, April 22, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), Egypt’s Minapharm, the regional leader in recombinant DNA technology, and its Berlin-based subsidiary ProBioGen AG announce the agreement to produce over 40 million doses per year of the world’s first registered vaccine against COVID-19, Sputnik V. The parties intend to commence technology transfer immediately. The rollout of the vaccine is expected in 3Q 2021. RDIF and Minapharm will initially…
Read more on this story »
Basic Profile
RDIF, Hualan Ink COVID-19 Vaccine Deal
Deal calls for production of over 100 million doses of Sputnik V vaccine in China.
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and Hualan Biological Bacterin Inc., a subsidiary company of one of China’s leading biopharmaceutical producers and the largest influenza vaccine manufacturer, Hualan Biological Engineering Inc., have entered an agreement to produce over 100 million doses per year of the Sputnik V vaccine in China.
View original story »
Basic Profile
Abzena blueprints $200M biologics plant in North Carolina, where it plans to hire 325
Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of complex biologics and bioconjugates has announced that the location of its new GMP manufacturing facility will be Sanford, North Carolina. The significant expansion of Abzena’s capacity is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas. Sanford will be Abzena’s 6th site in a global network providing integrated solutions…
Read more on this story »
Basic Profile
Nexus Pharmaceuticals sets month for $100M plant opening, preps drug for treating Covid patients
PLEASANT PRAIRIE, WI.–Nexus Pharmaceuticals Inc. plans to complete its nearly $100 million Pleasant Prairie sterile injectables plant in April 2021 and a company executive said it will help address the United States’ reliance on foreign pharmaceutical suppliers magnified by the Covid-19 pandemic.
Read more on this story »
Basic Profile
Resilience Continues Expansion with Acquisition of Biologics Manufacturing Company Ology Bioservices
Ology Bio, based in Alachua, Florida, develops and manufactures drugs and biologics for commercial customers as well as the U.S. government, with more than $1.8 billion in government contracts awarded. The acquisition provides Resilience with 300 skilled employees as well as more than 200,000 square feet of manufacturing, office, process development and quality assurance and quality control space across locations in Florida, California and Maryland, with additional expansion projects underway.
View original story »
Basic Profile
Progenity and Ionis Pharmaceuticals Enter into Agreement
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced an agreement with Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, to evaluate the safety, tolerability and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of antisense oligonucleotides, developed and manufactured by Ionis. Ionis’ novel antisense therapies are designed to target mRNA in a highly…
Read more on this story »
Basic Profile
Crystec launch a new R&D centre in Haimen, Jiangsu province, China
Crystec are pleased to announce the opening of a new subsidiary, Nantong Crystec Pharmaceutical R&D Co. Ltd., and research facility, located at Haimen Science and Technology Park in Haimen City, Jiangsu Province, China. Crystec’s new R&D centre has been established following an invitation to participate in the Yangtze Delta Advanced Drug Development platform jointly funded by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, and the Haimen government. The platform, which has received £550m equivalent in investment,…
Read more on this story »
Basic Profile
Formulationbio Newly Launches Disintegrant Excipients for Pharmaceutical Preparation
Excipients play an indispensable role in the process of pharmaceutical preparation. Disintegrants are added to a formulation to promote the drug release. To make disintegrant excipients easily accessible for scientists and researchers, Formulationbio recently announced that it now provides a wide range of disintegrant excipients that are frequently used…
Read more on this story »
Basic Profile
Chime Biologics Expands CDMO Capabilities
（March 26,2021, Wuhan） Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of US$190 million Series A+ investment from institutional investors in which over $100 million investment has already been closed today. This round financing was led by VMS Group and followed by Fidelity International and Panacea Venture. Earlier in February 2020 Chime Biologics has just completed its Series A financing of US$125 million.
View original story »
Basic Profile
KD Pharma Acquires Rohner AG Manufacturing Assets
BIOGGIO, SWITZERLAND – March 29, 2021 – The KD Pharma Group has acquired the manufacturing assets of the former Rohner AG. The assets give KD Pharma access to new complementary technologies that will allow the company to further expand its pharmaceutical contract manufacturing (“CDMO”) business. In addition, KD Pharma has strengthened its CDMO team by hiring several key personnel from the former Rohner team.
View original story »
Basic Profile
Jubilant, Novavax Enter COVID-19 Vaccine Partnership
Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharma Limited, announced that it has entered into a non-exclusive manufacturing agreement with Novavax, a biotechnology company developing next-generation vaccines for serious infectious diseases, to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373. Under the terms of the agreement, Jubilant HollisterStier’s Spokane, Washington facility has begun production activities of NVX-CoV2373 final drug product intended for commercial distribution in the United…
Read more on this story »
Basic Profile
CureVac, Celonic Enter COVID-19 Vax Mfg. Pact
TÜBINGEN, Germany/ BOSTON, USA/ BASEL, Switzerland, March 30, 2021 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the development and production of Advanced Therapy Medicinal Products (ATMPs) and mammalian cell line-expressed bio-therapeutics, today announced their partnership for the production of CureVac’s…
Read more on this story »
Basic Profile
National Resilience, months after launching with $800M, snags Sanofi biomanufacturing plant
A few short months after its launch, biomanufacturing and technology company National Resilience, led by former Novavax chief Rahul Singhvi, is moving forward with its ambitious expansion plans. Resilience has picked up two commercial facilities in Canada and the U.S., lifting its North American footprint to more than 750,000 square feet. The company set out late last year to establish a network of biopharma manufacturing sites with backing from leading venture firms and an impressive roster of executives and board members. The expansion…
Read more on this story »
Basic Profile
Asymchem Expands Manufacturing Capacity for Oligonucleotides
TEDA TIANJIN, P.R. China, March 25, 2021: Asymchem (stock code: 002821.SZ), is excited to announce a dedicated expansion of our API manufacturing facilities to provide clients with peptide and oligonucleotide products and meet the research and development needs of this expanding area of therapeutics. “Oligonucleotide-based therapies hold great promise to treat a broad spectrum of diseases and genetic conditions, and Asymchem is committed to investing in the infrastructure and expertise to help our customers bring these therapies to market with rapid, cost-effective…
Read more on this story »
Basic Profile
Biocentriq™ and Kytopen® Partner to Demonstrate Impact of Transformative Technology On Cell Therapy Manufacturing
BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, announces its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology (MIT). “Our mission at BioCentriq is to work with innovative industry partners like Kytopen to advance the production and manufacturing of cell and gene therapies, making them accessible and affordable for the patients who so desperately need them” said Haro Hartounian, Ph.D. and SVP, general manager, BioCentriq. “This…
Read more on this story »
Basic Profile
China-based CDMO will invest $15.8 million in North Carolina facility.
Brevard, N.C. – Raybow USA Inc, the North American unit of a global provider of outsourced pharmaceutical process development and manufacturing services, will expand its operations in North Carolina, tripling both its capacity and workforce. The company plans to add 74 jobs over the coming five years and will invest $15,800,000 at the Brevard facility. Raybow USA was founded as PharmAgra Labs in 1999 by two North Carolina entrepreneurs. Today, the Brevard-based company is the North American unit of China’s Raybow Pharmaceuticals, a publicly-held contract development…
Read more on this story »
Basic Profile
- Total Results: 573
- Total Pages: 12
Pharmaceutical News
Keeping the latest and up-to-date news on our directory companies is a key activity of the editorial team.
We support companies directly through the profiles to allow them update their profile with the latest news and company announcements. Search fields are provided so that you can access news by company name, sector e.g research, manufacturing, equipment, packaging or geography.
The global news is updated daily and its aim is to provide you as a directory user with the information needed to make good buying or supply choices. News covers companies operating within the pharmaceutical, biotechnology, medical device and nutraceutical sectors.
Also through our software applications you can evaluate, rate and score news and company announcements to support corporate risk management activities. Through the software applications it is possible to supplement and add your own news items, keeping a library of news activities on any company identified through the directory.
Take the Next Step
Should you have any questions or require further information please contact us ...
Contact the support team »
Check if your company is listed and claim your online profile ...
Search for your company listing »
If you're not listed in the directory and you want to build a public profile, register for an account ...
Register for an account to build a profile »
Apply for a free trial of our Supplier Management Software ...
Register for an account to trial the software »
